The FDA cleared a miniaturized and disposable sensor patch designed to detect early complications from IV drug infusions—including potentially harmful leaks of medication into the surrounding tissue, such as from a misplaced needle.

Philips announced plans to integrate BioIntelliSense’s health-tracking sticker into its remote patient monitoring programs, designed to observe at-risk patients after they head home from the hospital.

Three months ago, the nation watched as COVID-19 patients overwhelmed New York City’s intensive care units, forcing some of its hospitals to convert cafeterias into wards and pitch tents in parking lots.

SOUTH SAN FRANCISCO, Calif.– Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Phase III IMagyn050 study showed that the addition of Tecentriq^® (atezolizumab) to Avastin^® (bevacizumab), paclitaxel and carboplatin did not meet its primary endpoint of progression-free survival (PFS) for the front-line treatment of women with newly-diagnosed advanced-stage ovarian cancer. Topline safety data indicate that safety for Tecentriq in combination with Avastin, paclitaxel and carboplatin was consistent with the known safety profile of the combination.

A who’s who of Big Pharma companies, including Pfizer, Johnson & Johnson and Merck, has banded together to bolster the development of new antibiotics. The companies announced Thursday the $1 billion AMR Action Fund, which aims to see two to four new antibiotics through approval by 2030.

Five years after kicking off a massive phase 3 program, Bayer has good news for its heart failure pill finerenone. The drug beat placebo at staving off progression of kidney disease and lowered the risk of heart attacks and strokes in patients with chronic kidney disease (CKD) and Type 2 diabetes.

Blackstone Life Sciences has hit the target for its latest fund, giving it $4.6 billion to place a series of big bets. The vehicle, which Blackstone claims is the largest life sciences private fund, has already committed close to $1 billion to companies including Alnylam and Reata Pharmaceuticals.

One key component of the immune system that prevents breast cancer cells from forming distant metastases is a group of cells called natural killer cells. How breast tumor cells evade this surveillance system is not fully understood.

Novartis has teamed up with smart inhaler developer Propeller Health to package and ship its digital medication-tracking platform alongside the Big Pharma’s newly approved asthma treatment in Europe.

It took a little longer than expected, but Biogen’s done it—along with partner Eisai, the Big Biotech has completed an FDA filing for aducanumab, the once-failed Alzheimer’s drug it resurrected just in time for Halloween.